Paul Manning
@paulmanning4991
Director
Building Verrica Pharmaceuticals Inc. as Director
- Website not added yet
- LinkedIn not added yet
- X not added yet
- Instagram not added yet
- Facebook not added yet
Founder Rating
1500
Everyone starts at 1500.
It only moves when two founders agree to a duel.
In context
ArcherDX, Inc. was founded in 2013 and has no closure on record. Among the 35,516 other companies founded in the 2010s we hold, those that closed lasted a median of 5 years.
Named alongside
- Benjamin CarverExecutive Officer
- Britton A. RussellExecutive Officer
- Christian LaPointeExecutive Officer
- Jason C. RyanDirector
- Jason MyersExecutive Officer, Director
- Jason W. MyersExecutive Officer, Director
- Joshua C. StahlExecutive Officer
- Joshua StahlExecutive Officer
At Blue Marlin Therapeutics, Inc.
- Sean StalfortPresident and Secretary
- Alexander FlemingExecutive Officer
- Graeme CurieExecutive Officer
- James StutzExecutive Officer
- John DonovanExecutive Officer, Director
- Lawrence SteinmanDirector
- Randolph JohnsonExecutive Officer
- Scott GeyerExecutive Officer
- Sean StalfortDirector
At Verrica Pharmaceuticals Inc.
- Anthony C. CavalloExecutive Officer
- David ZawitzExecutive Officer
- Diem B. NguyenDirector
- Gavin B. CorcoranDirector
- Glenn OclassenDirector
- James C. ReebalsExecutive Officer, Promoter
- Jayson RiegerDirector
- John KirbyExecutive Officer
Contribution
Paul's ideas, decisions and failures appear here once this profile is claimed.
Companies
- Verrica Pharmaceuticals Inc.Pharmaceutical Preparations; listed on Nasdaq as VRCA; filing with the SEC since 2015Director · Pharmaceuticals · WEST CHESTER, United States
- ArcherDX, Inc.In Vitro & In Vivo Diagnostic Substances; filing with the SEC since 2018Director · In Vitro & In Vivo Diagnostic Substances · BOULDER, United States · Founded 2013
- Tolerion, Inc.Director · Biotechnology · SOUTH SAN FRANCISCO, United States
- Blue Marlin Therapeutics, Inc.Chief Executive Officer · Biotechnology · CHARLOTTESVILLE, United States · Founded 2025